AbbVievs.Zoetis
ABBV vs ZTS · both in Big pharma, part of the Medicine, pharma & life science value chain: Large, diversified pharmaceutical groups with broad portfolios across therapeutic areas.
AbbVie is about 15× larger than Zoetis by market cap; Zoetis trades at the lower P/E (11.5 vs 70.2); year to date, AbbVie leads (+15.8% vs −38.7%).
Side by side
| ABBV | ZTS | |
|---|---|---|
| Market cap | $443B | $30.2B |
| Price | $265.79 | $77.29 |
| Today | +0.5% | +0.2% |
| Return YTD | +15.8% | −38.7% |
| Return 1Y | +25.6% | −50.7% |
| P/E | 70.2 | 11.5 |
| P/S | 6.9 | 3.2 |
| P/B | 312.1 | 9.6 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
AbbVieABBV
Skyrizi and Rinvoq carry the immunology franchise. Oncology and neuroscience follow, plus the aesthetics business built around Botox.
Full ABBV profile →ZoetisZTS
Spun out of Pfizer in 2013 to sell animal medicines and vaccines. Simparica handles parasites while Librela and Solensia treat pain, with pets on one side of the business and livestock on the other.
Full ZTS profile →More ABBV & ZTS comparisons
Other head-to-heads in the Big pharma segment.